Open to new collaborations · Amman, Jordan

Hi, I'm Yousef. A research biostatistician.

I provide the biostatistics your clinical research needs to reach high-impact, top-tier journals.

My one rule

Methods come first. Even when the data is inconvenient.

§ 01 The standard

Built for high-impact journals.

Every analysis follows the reporting guidelines and ships with reproducible R code, ready for the most rigorous methodological review.

Publications

Top Impact Factor

Journal Quartile

Portrait of Yousef Alghzawi — Yousef Alghzawi, Biostatistician

§ 02 What I do

Four ways I can help.

All services →

S/01 Publication-Grade Analysis Raw data to a submission-ready paper. 2 to 4 weeks S/02 Systematic Review & Meta-Analysis PRISMA-compliant evidence synthesis. 1 to 3 weeks S/03 Trial Statistical Strategy Power and plan before you enroll. 1 to 2 weeks S/04 Methods Audit & Risk Assessment An independent check before you submit. 2 to 3 weeks

§ 03 A few studies

Recent collaborations.

Scroll to explore →

Hematologic Oncology - Survival

Published - Blood (ASH), 1st Author

Is a Second Transplant Worth It?

Relapsed leukemia and lymphoma. Survival modeling that separates what the procedure costs from what the disease takes.

View case study →

Radiation or Surgery for Early Lung Cancer?

Thoracic Oncology - Meta-Regression

ASCO 2026 - 1st Author

Radiation or Surgery for Early Lung Cancer?

Propensity-matched pooling, with the missing hazard ratios rebuilt from raw event counts.

View case study →

Structural Cardiology - Proportions

Published - JACC, 1st Author

Keeping the Outflow Open in TMVR

No head-to-head trials existed, so the comparison was built technique by technique.

View case study →

Stroke Neurology - NMA

Published - Int J Neuroscience

Thrombolysis After the Window Closes

One evidence network, estimated in two statistical frameworks that agreed.

View case study →

Stroke Neurology - Rare Events

Published - J Clinical Neurology

Cerebrolysin and the Bleeding Question

A harm too rare for default models. Rare-event methods, plus a check that the evidence was even big enough.

View case study →

Cardiac Surgery - Proportions

Published - Thorac Cardiovasc Surg

Stent versus Trunk

Two repairs for a torn aorta, compared through auditable proportion pooling.

View case study →

Vascular Surgery - Bayesian

Published - Ann Vasc Surg

Pooling the Unpoolable

A Bayesian model that turns case reports into strategy-level survival odds.

View case study →

Cancer Epidemiology - Registry

ASCO 2026 - Paper In Revision

The Brain Tumor After the Blood Cancer

More than 830,000 registry patients, with death treated as the competing risk it is.

View case study →

Vascular Surgery - Meta-Analysis

Under Review

Six Outcomes, One Stable Answer

A sensitivity framework that demonstrates stability instead of assuming it.

View case study →

Methods Story - NMA

In Preparation - Masked

The Network That Wasn't Connected

Two evidence islands, and one bridge tested as a sensitivity rather than assumed as fact.

View case study →

Thirty-Four Specialists, One Whitespace Bug

Methods Story - Exact Inference

Delivered - Masked

Thirty-Four Specialists, One Whitespace Bug

Exact inference at a small sample size, and the data-quality catch that changed the headline count.

View case study →

The promise

Statistics ready for the journal you're aiming at.

§ 04 In print

Published in high-impact journals.

All publications →

Immunotherapy The Role of AI in Predicting Immunotherapy Outcomes Based on Gut Microbiota Composition Leen Alhassan, Bassel Alrabadi, et al., incl. Yousef Alghzawi 2026 → Annals of Vascular Surgery Aortoesophageal Fistula: Mending the Lethal Connection Noor Abu Hantash, Hazem El Beyrouti, Yousef Alghzawi, et al. 2026 → J Clin Oncol (ASCO 2026) Open, Laparoscopic, versus Robotic Surgery for Siewert Type II/III Adenocarcinoma Bara Hammadeh, Faizan Sheraz, Yousef Alghzawi, et al. 2026 → J Clin Oncol (ASCO 2026) Incidence, Risk Factors, and Survival of Secondary Primary CNS Tumors Following Hematologic Malignancies Bara Hammadeh, Yousef Alghzawi, Dana Tarawneh, et al. 2026 →

§ 05 How we'd work

How working together goes.

Submit Inquiry

Tell me your study and target journal.

Scoping Call

We align on endpoints and a plan.

Analysis

Full analysis, figures, and reproducible code.

Revisions

You review; I refine for submission.

Reviewer Support

I answer the statistical queries.

§ 06 My toolkit

What I build with.

R / RStudio SPSS PostgreSQL tidyverse survival meta / metafor ggplot2 lme4 tableone cmprsk R Markdown Joinpoint RevMan

§ 07 Before you ask

Questions I get a lot.

How do you protect my data and confidentiality?

I sign an NDA and a data-handling agreement before any data is transferred. Datasets are stored encrypted and deleted on completion unless we agree otherwise. I am equally comfortable working with fully de-identified data.

What if reviewers question the statistical methods?

Post-submission support is included. I draft point-by-point statistical responses and run any additional sensitivity or subgroup analyses reviewers request. My standard is simple: the statistics will not be why your paper is rejected.

How do you handle authorship and acknowledgment?

My role is acknowledged in the methods section or the author list depending on the level of contribution. We agree on this in writing, upfront, during scoping. No surprises.

Can you work with my existing dataset and analysis?

Yes. I can audit an existing analysis, clean and restructure your dataset, or start from raw data. I work with SPSS (.sav), Excel, CSV, REDCap exports, and SQL databases.

What is the typical timeline for a project?

Most original-research projects take 2 to 4 weeks and meta-analyses 1 to 3 weeks. The estimate depends on dataset complexity, number of endpoints, and revision cycles. You get a specific timeline during scoping.

Do you help with study design, or only the analysis?

Both. I offer pre-study consultation including sample-size calculations, endpoint definitions, and design review, and I can join at any stage from protocol development to post-hoc analysis.